Biomarker exploration of microRNA-203 as a promising substrate for predicting poor survival outcome in colorectal cancer

Table 1 Main characteristics of the studies selected for the meta-analysis

First author	Year	Country	Ethnicity	M/F	N	Age	TNM stage	Sample souce	Methods	Endogenous control	Endpoints	Median follow-up time (months)	Hazard ratio
Schetter et al	2008	USA	Non-Asians	66/18	84	65	I-IV	Tissue	RT-PCR	U6	OS	68	3.10 (1.50–6.40)
Bovell et al	2013	USA	Non-Asians	170/175	345	65	I-IV	Tissue	RT-PCR	U6	OS	228	1.90 (1.05–3.42)
Tao et al	2014	China	Asians	47/43	90	70	I-IV	Tissue	RT-PCR	U6	OS	27	1.38 (0.77–2.48)
Deng et al. (Cohort 1)	2016	China	Asians	39/33	72	50	I-IV	Tissue	RT-PCR	U6	OS	84	0.62 (0.32–1.20)
Deng et al. (Cohort 2)	2016	China	Asians	39/33	72	50	I-IV	Serum	RT-PCR	U6	OS	84	0.36 (0.20–0.64)
Kingham et al. (Cohort 1)	2017	USA	Non-Asians	57/34	91	59	I-IV	Tissue	RT-PCR	miR-331	OS	192	1.92 (1.17–3.13)
Kingham et al. (Cohort 2)	2017	USA	Non-Asians	31/15	46	56	I-IV	Serum	RT-PCR	miR-331	OS	60	1.98 (1.14–3.42)
Takano et al	2017	Japan	Asians	147/93	240	NA	I-IV	Serum	RT-PCR	miR-16	OS	54	2.27 (1.31–4.09)
Hur et al. (Cohort 1-tissue)	2017	Japan	Asians	90/64	154	68	I-IV	Tissue	RT-PCR	Cel-miR-39	OS	72	1.56 (0.80–3.05)
Hur et al. (Cohort 1-serum)	2017	Japan	Asians	107/79	186	68	I-IV	Serum	RT-PCR	Cel-miR-39	OS	72	2.14 (1.09–4.21)
Hur et al. (Cohort 1-serum)	2017	Japan	Asians	87/57	144	68	I-IV	Serum	RT-PCR	Cel-miR-39	OS	72	2.35 (1.34–4.12)

ISSN: 1471-2407